Skip to main content
Back to homepage
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Annual Reports & Proxies
SEC Filings
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Menu
Press Releases
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Annual Reports & Proxies
SEC Filings
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
December 05, 2018
ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates
Download
PDF format download (opens in new window)
November 27, 2018
ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Download
PDF format download (opens in new window)
November 14, 2018
ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting
Download
PDF format download (opens in new window)
November 08, 2018
ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Download
PDF format download (opens in new window)
August 07, 2018
ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Download
PDF format download (opens in new window)
April 25, 2018
ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors
Download
PDF format download (opens in new window)
April 11, 2018
ADC Therapeutics to Present Two New Investigational Antibody-Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
Download
PDF format download (opens in new window)